Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps.
Mahajan A., Taliun D., Thurner M., Robertson NR., Torres JM., Rayner NW., Payne AJ., Steinthorsdottir V., Scott RA., Grarup N., Cook JP., Schmidt EM., Wuttke M., Sarnowski C., Mägi R., Nano J., Gieger C., Trompet S., Lecoeur C., Preuss MH., Prins BP., Guo X., Bielak LF., Below JE., Bowden DW., Chambers JC., Kim YJ., Ng MCY., Petty LE., Sim X., Zhang W., Bennett AJ., Bork-Jensen J., Brummett CM., Canouil M., Ec Kardt K-U., Fischer K., Kardia SLR., Kronenberg F., Läll K., Liu C-T., Locke AE., Luan J., Ntalla I., Nylander V., Schönherr S., Schurmann C., Yengo L., Bottinger EP., Brandslund I., Christensen C., Dedoussis G., Florez JC., Ford I., Franco OH., Frayling TM., Giedraitis V., Hackinger S., Hattersley AT., Herder C., Ikram MA., Ingelsson M., Jørgensen ME., Jørgensen T., Kriebel J., Kuusisto J., Ligthart S., Lindgren CM., Linneberg A., Lyssenko V., Mamakou V., Meitinger T., Mohlke KL., Morris AD., Nadkarni G., Pankow JS., Peters A., Sattar N., Stančáková A., Strauch K., Taylor KD., Thorand B., Thorleifsson G., Thorsteinsdottir U., Tuomilehto J., Witte DR., Dupuis J., Peyser PA., Zeggini E., Loos RJF., Froguel P., Ingelsson E., Lind L., Groop L., Laakso M., Collins FS., Jukema JW., Palmer CNA., Grallert H., Metspalu A., Dehghan A., Köttgen A., Abecasis GR., Meigs JB., Rotter JI., Marchini J., Pedersen O., Hansen T., Langenberg C., Wareham NJ., Stefansson K., Gloyn AL., Morris AP., Boehnke M., McCarthy MI.
We expanded GWAS discovery for type 2 diabetes (T2D) by combining data from 898,130 European-descent individuals (9% cases), after imputation to high-density reference panels. With these data, we (i) extend the inventory of T2D-risk variants (243 loci, 135 newly implicated in T2D predisposition, comprising 403 distinct association signals); (ii) enrich discovery of lower-frequency risk alleles (80 index variants with minor allele frequency <5%, 14 with estimated allelic odds ratio >2); (iii) substantially improve fine-mapping of causal variants (at 51 signals, one variant accounted for >80% posterior probability of association (PPA)); (iv) extend fine-mapping through integration of tissue-specific epigenomic information (islet regulatory annotations extend the number of variants with PPA >80% to 73); (v) highlight validated therapeutic targets (18 genes with associations attributable to coding variants); and (vi) demonstrate enhanced potential for clinical translation (genome-wide chip heritability explains 18% of T2D risk; individuals in the extremes of a T2D polygenic risk score differ more than ninefold in prevalence).